CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

FAYUVI

FAYUVINeutral
AI Analysis

Summary

FAYUVI is indicated for treatment of neurologic manifestations of MPS IIIA (Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function. No specific clinical or regulatory event details are provided in this announcement.

Importance:1/10
Sentiment:
0.00
rare diseasepediatricneurologicalMPS IIIASanfilippo syndrome

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on October 14, 2026 5:22 PM

Read Original